Elkfork Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Elkfork Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$7.12M	Buy	55,572 +6,534	+13%	+$876K	0.17%	112
2019 Q2	$6.99M	Buy	49,038 +3,036	+7%	+$408K	0.17%	121
2019 Q1	$6.58M	Buy	46,002 +18,744	+69%	+$2.44M	0.17%	129
2018 Q4	$3.38M	Buy	27,258 +25,850	+1,836%	+$3.83M	0.1%	193
2018 Q3	$237K	Buy	1,408 +1,232	+700%	+$212K	0.01%	808
2018 Q2	$30K	Buy	+176	New	+$28.8K	﹤0.01%	987

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Elkfork Partners's JAZZ Position: Q3 2019 in Review

Elkfork Partners increased its Jazz Pharmaceuticals (JAZZ) stake by 13% in Q3 2019, buying an estimated $876K and bringing the position to 55,572 shares worth $7.12M. The position accounts for 0.17% of the portfolio, ranked #112.

Elkfork Partners first reported a position in JAZZ in Q2 2018 and has held it in 6 quarters since. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

Elkfork Partners held 55,572 shares of Jazz Pharmaceuticals worth $7.12M as of Q3 2019.
Elkfork Partners bought 6,534 Jazz Pharmaceuticals shares in Q3 2019, an estimated $876K.
Jazz Pharmaceuticals made up 0.17% of Elkfork Partners's portfolio in Q3 2019, its #112 holding.
Elkfork Partners first reported a position in Jazz Pharmaceuticals in Q2 2018 and has held it in 6 quarters since.
406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.